Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IDH2 Mutation”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Early research (Phase 1)Active Not RecruitingNCT04521686
What this trial is testing

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Eli Lilly and Company 200
Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839
What this trial is testing

Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

Who this might be right for
Acute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more
Shen yang 148
Testing effectiveness (Phase 2)Study completedNCT01915498
What this trial is testing

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Who this might be right for
Hematologic Neoplasms
Celgene 345
Not applicableApproved For MarketingNCT05592743
What this trial is testing

Vorasidenib Expanded Access Program

Who this might be right for
GliomaRecurrenceDisease Attributes+10 more
Servier
Testing effectiveness (Phase 2)Temporarily pausedNCT03728335
What this trial is testing

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia
City of Hope Medical Center 35
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78
Testing effectiveness (Phase 2)Looking for participantsNCT03683433
What this trial is testing

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Who this might be right for
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 50
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Early research (Phase 1)Looking for participantsNCT05873686
What this trial is testing

Clinical Study of NXP900 in Subjects With Advanced Cancers

Who this might be right for
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal Cancer+3 more
Nuvectis Pharma, Inc. 140
Testing effectiveness (Phase 2)Study completedNCT04281498
What this trial is testing

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Who this might be right for
Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
John Mascarenhas 6
Very early researchActive Not RecruitingNCT05406700
What this trial is testing

Niraparib In Recurrent IDH 1/2 Gliomas

Who this might be right for
Low-grade GliomaIDH2 Gene MutationRecurrent Glioma+2 more
Massachusetts General Hospital 16
Testing effectiveness (Phase 2)Looking for participantsNCT07286292
What this trial is testing

Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

Who this might be right for
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
Institut de Recherches Internationales Servier (I.R.I.S.) 10
Early research (Phase 1)Study completedNCT05102370
What this trial is testing

Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Who this might be right for
Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined Significance
Memorial Sloan Kettering Cancer Center 4
Not applicableUnknownNCT04369287
What this trial is testing

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIDH2 Gene Mutation
Istituto Clinico Humanitas 654
Testing effectiveness (Phase 2)Study completedNCT02273739
What this trial is testing

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Who this might be right for
Solid TumorGliomaAngioimmunoblastic T-cell Lymphoma+2 more
Celgene 21
Testing effectiveness (Phase 2)Looking for participantsNCT03383575
What this trial is testing

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT03825796
What this trial is testing

CPX-351 Plus Enasidenib for Relapsed AML

Who this might be right for
Recurrent Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center 2
Testing effectiveness (Phase 2)Ended earlyNCT04092179
What this trial is testing

Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Who this might be right for
Acute Myeloid LeukemiaRelapsed CancerRefractory Cancer+1 more
University Health Network, Toronto 27
Testing effectiveness (Phase 2)Study completedNCT04522895
What this trial is testing

IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
Heinrich-Heine University, Duesseldorf 50
Next Page